Valeant Pharma (VRX) 1Q16 Was A Clean-Up Quarter - Guggenheim
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Valeant Pharmaceuticals To Webcast 2016 Annual Meeting Of Shareholders
June 7, 2016 5:00 PM EDTLAVAL, Quebec, June 7, 2016 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that it will conduct a live webcast of the company's annual meeting of shareholders for the year ended December 31, 2015. The meeting and webcast will be held on Tuesday, June 14, 2016 at 9:00 a.m. ET at the International Headquarters,... More
Valeant Pharmaceuticals Reports First Quarter 2016 Financial Results
June 7, 2016 6:00 AM EDTLAVAL, Quebec, June 7, 2016 /PRNewswire/ --
Total Revenues of $2.4 billion, an increase of 9% versus the first quarter of 2015 (restated) GAAP EPS ($1.08); Adjusted EPS (non-GAAP) $1.27 GAAP Cash Flow from Operations was $558 million, an increase of 14% versus the first quarter of 2015 (restated) Updated Full Year 2016 Guidance: Total Revenue updated to $9.9 - $10.1 billion from $11.0 - $11.2 billion Adjusted EPS (non-GAAP) updated to $6.60 - $7.00 from $8.50 - $9.50 Adjusted EBITDA (non-GAAP) is updated to $4.80 - $4.95 billion from $5.60 - $5.80 billionValeant Pharmaceuticals International,... More
